AB-1002 is administered via antegrade intracoronary artery infusion. The Food and Drug Administration (FDA) has granted Fast Track designation to AB-1002 for the treatment of congestive heart failure ...

First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure Trial enrolled 11 participants in ...

Atrial fibrillation (AF) and chronic heart failure (CHF) are two major and even growing cardiovascular conditions that often coexist. However, few data are available to guide treatment of AF in ...

A critical review of cell-based and cell product-based therapies for the treatment of heart failure details 20 years of completed and ongoing clinical trials. While none has yet gained medical ...

Aims Sleep disordered breathing (SDB) may contribute to disease progression in patients with chronic heart failure (CHF). The objective of this observational study was to evaluate whether SDB is a ...

Utilization of the four pillars in heart failure therapy are highlighted as aggressive first-line treatment strategies. This is a video synopsis/summary of a panel discussion involving Robert Groves, ...

"We believe these encouraging early results in patients with advanced heart failure are important for the congestive heart failure community, as they bring hope to a sub-population where treatment ...

Panelists discuss how β-blockers remain foundational therapy for heart failure with reduced ejection fraction (using evidence-based agents like carvedilol, metoprolol succinate, or bisoprolol) with ...